KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.98

Four months of treatment with anakinra combined with glucocorticoids for giant cell arteritis: a multicenter, randomized, double-blind, placebo-controlled trial.

Hubert de Boysson, Kim Heang Ly, Loïk Geffray, Thomas Quemeneur, Eric Liozon, Holy Bezanahary, Noémie Le Gouellec, Alexandra Audemard, Anael Dumont, Samuel Deshayes, Jonathan Boutemy, Gwénola Maigné, Nicolas Martin Silva, Audrey Sultan, Brigitte Le Mauff, Gauthier Petit, Jean-Jacques Parienti, Achille Aouba

Arthritis Res Ther 27(1) 122

PMID40483523
PMCIDPMC12144695
DOI10.1186/s13075-025-03493-z
发表日期2025-06-07
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

BACKGROUND: Efficacy and tolerance of anakinra (ANK) in the treatment of giant cell arteritis (GCA) need to be assessed. METHODS: This phase 3 study (NCT02902731) was a prospective multicenter, randomized, double-blind, placebo-controlled trial conducted over a 52-week period. GCA patients were randomized 1:1. From inclusion to week 16 (W16), patients in the anakinra (ANK) group received a daily subcutaneous injection of 100 mg of anakinra, whereas patients in the other group received placebo (PBO). In both arms, glucocorticoid (GC) discontinuation was planned at week 52 (W52). The endpoints were the relapse rates at W16, W26, and W52 and the completion of GC tapering. Given the emergence of the SARS-CoV-2 pandemic, the study was stopped prematurely. RESULTS: Thirty patients with new GCA diagnoses from 5 centers were randomized as follows: 17 in the ANK group and 13 in the PBO group. During the first 16 weeks, the relapse rates were 12% (n = 2) and 23% (n = 3) in the ANK and PBO groups, respectively (p = 0.63). At week 26, 12 (40%) patients had relapsed: 8 (47%) in the ANK group and 4 (31%) in the PBO group (p = 0.47). At W52, the relapse rate (overall, 50%) did not differ between the ANK group (53%; 9/17 patients) and the PBO group (46%; 6/13 patients) (p = 1). Two patients in each group discontinued GCs (p = 0.87). Seven serious AEs were reported in five patients, including 4 in patients receiving ANK. CONCLUSIONS: Although prematurely discontinued, this study does not support the use of 4 months of treatment with anakinra combined with GCs to reduce the risk of relapse or GC exposure. TRIAL REGISTRATION: ClinicalTrials.gov NCT02902731.

KM 提取结果

1 个 Figure · 1 个 KM 面板

进入结果中心
KM Figure1 个面板

Fig. 2

Fig. 2 Relapse-free survival of patients receiving anakinra or placebo

Relapse-free_survival

relapse-free survival

Fig. 2 · Panel Relapse-free_survival

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel Relapse-free_survival 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 1 条曲线 1:extreme jump曲线 1:off origin start曲线 1:extreme upward reversal
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Study protocol
非 KM Figure
Fig. 3Fig. 3 Mean prednisone doses in patients receiving anakinra or placebo over a 52-week duration
非 KM Figure